Methadone Hydrochloride Market

Global Methadone Hydrochloride Market Size (2023 to 2028)

The global methadone hydrochloride market is expected to be worth USD 86.12 million by 2028 from USD 68.12 million in 2023, growing at a CAGR of 4.8% from 2023 to 2028.

Impact of COVID-19 on the global methadone hydrochloride market:

The healthcare industry encountered significant challenges as the outbreak caused widespread confusion and misinformation, placing immense pressure on hospitals and healthcare systems worldwide. For instance, in May 2020, the Centers for Disease Control and Prevention (CDC) collaborated with government agencies and research institutes to enhance testing capacity, improve case detection, and implement contact tracing across all U.S. states. Their objective was to facilitate the reopening of the country amidst the COVID-19 pandemic. Additionally, during the lockdown period, some countries responded to the reduced accessibility of COVID-19 treatment services by taking steps to improve access to opiate-substitution medication. For instance, in the U.K., they allowed pharmacies to dispense methadone, thereby creating low-threshold services and reducing barriers for individuals seeking such medication.

MARKET DRIVERS:

The growing prevalence of post-surgical treatment pain is one of the key factors driving the growth of the methadone hydrochloride market. The number of people suffering from pain arising from therapeutic and post-surgical treatments for cancer and other chronic diseases is on the rise worldwide. Patients who require continuous pain management over extended periods and have limited alternative drug options often turn to methadone to alleviate their severe pain. A report from the BJS Society indicates that acute postoperative pain is a frequent occurrence, with approximately 20 percent of patients experiencing severe pain within the initial 24 hours after surgery. Notably, this percentage has remained relatively consistent over the past three decades.

The growing drug overdose globally is another major factor propelling the global methadone hydrochloride market growth. Methadone is used to treat opioid use disorders, serving as a remedy for opioid withdrawal symptoms. It can be employed for detoxification in shorter durations or as a maintenance therapy for prolonged treatment. According to the UNODC World Drug Report 2022, drug usage worldwide saw a significant increase, with around 284 million people aged 15-64 reported using drugs in 2020, representing a 26% rise compared to the previous decade. Notably, the current generation of young individuals in many countries is exhibiting higher levels of drug use than the previous generation. Governments have taken proactive measures to address drug abuse and promote healthier lifestyles. For instance, in March 2012, the UNODC collaborated with the National Drug Dependence Treatment Centre of India to establish the country's inaugural methadone maintenance treatment center at the Civil Hospital in Kapurthala, Punjab and this center aims to cater to the needs of heroin and opioid addicts, offering them effective treatment and support.

MARKET RESTRAINTS:

The side effects associated with using methadone hydrochloride, such as nausea, sleepiness, vomiting, tiredness, dizziness, and stomach pain, is one of the significant factors hampering the global market growth. Moreover, there is a risk of patients developing an addiction to methadone, which is a concerning issue for many individuals. Even when prescribed for pain, the relief provided by methadone can lead to chemical dependency, especially in patients suffering from chronic pain. Consequently, some physicians are cautious about prescribing methadone to their patients. Those who do prescribe it take extra precautions, closely monitoring their patients' prescriptions and being vigilant for signs of misuse that may indicate the development of dependency. Psychological side effects can have serious implications, necessitating the attention of supervising medical personnel. To address these concerns, some healthcare providers may lower the dosage of methadone or switch the patient to an alternative medication like buprenorphine. These factors possibly hamper the growth rate of the methadone hydrochloride market.

REPORT COVERAGE:

The global market of methadone hydrochloride has been segmented into product type, applications, routes of application, distribution channel and region.

Methadone Hydrochloride Market - By Product Type:

• Solution
• Tablet
• Others

The tablet segment is expected to hold the largest share of the global market during the forecast period. An influx of new product launches and approvals from regulatory authorities majorly drive the growth of the tablet segment in the global market. There are some potential risks associated with Methadone Hydrochloride Oral Solution, as its usage exposes patients and other users to the dangers of opioid addiction, abuse, and misuse. There is a concern regarding dosing errors arising from confusion between milligrams (mg) and milliliters (mL) when using the oral solution, especially considering the availability of different concentrations of methadone hydrochloride solutions. These errors can lead to accidental overdose and, in severe cases, even fatalities.

Methadone Hydrochloride Market - By Application:

• Opiated Withdrawal
• Chronic Pain
• Others

The chronic pain segment is anticipated to account for the leading share of the global market during the forecast period. Factors such as the growing prevalence of pain related to therapeutic and post-surgical treatments for cancer and other chronic diseases drive the chronic pain segment in the global market. Approximately 33% of all adults suffer from multiple chronic conditions, and chronic diseases were responsible for around 35 million out of 58 million deaths in 2005.

The opiated withdrawal segment is expected to occupy a considerable share of the worldwide market during the forecast period. There is a significant rise in opioid withdrawal syndrome, primarily due to the increasing number of drug overdose cases. In the U.S., opioids were involved in nearly 75% of the 91,799 overdose deaths recorded in 2020.

Methadone Hydrochloride Market - By Route of Administration:

• Injectables
• Oral

Based on the route of administration, the oral segment is predicted to account for the leading share of the global market during the forecast period. The oral route of the application provides ease of ingestion, helps avoid pain, ensures patient safety, encourages good patient compliance, and offers versatility in accommodating various types of drugs. These benefits have contributed to the widespread preference and success of the oral segment in the global market.

On the other hand, the injectables segment is estimated to hold a considerable share of the global market during the forecast period. Injectable administration is commonly employed alongside these methods, particularly for chronic pain management, where a transdermal patch is considered an effective option.

Methadone Hydrochloride Market - By Distribution Channels:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on end-users, the hospital pharmacies segment is expected to continue dominating the market throughout the forecast period. Hospitals serve as central hubs for patient care and complex surgical procedures. The increasing preference of patients for hospitals as screening venues, the rise in the number of opioid overdose cases, and the agreement of hospitals with specialty pharmacy service providers drive the growth of the hospital pharmacies segment in the global market. The rising awareness among the general population and the implementation of screening programs in healthcare facilities further propel segmental growth.

On the other hand, the retail pharmacies segment is projected to hold a considerable share of the global market in the coming years.

Methadone Hydrochloride Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa

North America dominated the market in 2022 and is estimated to continue its domination in the global market throughout the forecast period. Factors such as the high prevalence of opioid and heroin abuse majorly propel the growth of the North American market. In 2021, preliminary estimates indicate more than 107,000 drug overdose deaths in the United States, surpassing the number of nearly 92,000 deaths recorded in 2020.

Europe holds a substantial share of the global market and is expected to witness a prominent CAGR in the coming years. Eastern and South-Eastern Europe, as well as Central Asia, show high rates of individuals undergoing treatment for opioid use disorders. The region is witnessing increased awareness about these disorders among the general population, coupled with growing healthcare spending, which will contribute to market expansion.

Latin America and the Middle East & Africa will witness a steady growth rate during the forecast period owing to the rise in the number of patients suffering from opioid dependency.

KEY MARKET PLAYERS:

Some of the notable key market players include Eli Lilly, Sanofi, Roxane Laboratories, Mallinckrodt, Siegfried Ltd, MACFARLAN SMITH, Tianjin Central Pharma, Hikma Pharmaceuticals PLC, Johnson Matthey, Temad Co, Embio LTD, Harman Finochem Ltd, and Rusan Pharma Ltd.

RECENT MARKET DEVELOPMENTS:

• In July 2023, Rusan Pharma launched the Navin Saxena Research and Technology (NSRT) center in Gujarat's Kandla special economic zone, investing $15 million in the facility. The center is dedicated to the research and production of drug-delivering transdermal patches. Rusan Pharma manufactures various medications, including the Fenstud fentanyl opioid pain patch, alongside sublingual, oral, and injectable drugs. With this new facility, India can tap into the $375 million global licensing market for niche categories targeted by NSRT, fostering innovation and participation in the pharmaceutical sector.
• In June 2021, Purdue Pharma LP recently announced that the U.S. Food and Drug Administration has accepted and filed their abbreviated new drug application for the vial dosage form of nalmefene hydrochloride injection. This particular formulation is intended to be used for the treatment of opioid overdose.